Antibody-Based Detection and Inhibition of Vaginolysin, the Gardnerella vaginalis Cytolysin by Randis, Tara M. et al.
Antibody-Based Detection and Inhibition of Vaginolysin,
the Gardnerella vaginalis Cytolysin
Tara M. Randis
1, Ritwij Kulkarni
1, Jorge L. Aguilar
1, Adam J. Ratner
1,2*
1Department of Pediatrics, Columbia University, New York, New York, United States of America, 2Department of Microbiology, Columbia University, New York, New York,
United States of America
Abstract
Bacterial vaginosis (BV) is the most common vaginal infection worldwide and is associated with significant adverse sequelae.
We have recently characterized vaginolysin (VLY), the human-specific cytotoxin produced by Gardnerella vaginalis and
believed to play a critical role in the pathogenesis of BV and its associated morbidities. We hypothesize that novel antibody-
based strategies may be useful for detection of VLY and for inhibition of its toxic effects on human cells. Using purified toxin
as an immunogen, we generated polyclonal rabbit immune serum (IS) against VLY. A western blot of G. vaginalis lysate was
probed with IS and a single band (57 kD) identified. Immunofluorescence techniques using IS detected VLY production by
G. vaginalis. In addition, we have developed a sandwich ELISA assay capable of VLY quantification at ng/ml concentrations
in the supernatant of growing G. vaginalis. To investigate the potential inhibitory role of IS on VLY-mediated cell lysis, we
exposed human erythrocytes to VLY or VLY pretreated with IS and determined the percent hemolysis. Pretreatment with IS
resulted in a significant reduction in VLY-mediated lysis. Similarly, both human cervical carcinoma cells and vaginal epithelial
cells exhibited reduced cytolysis following exposure to VLY with IS compared to VLY alone. These results confirm that
antibody-based techniques are an effective means of VLY detection. Furthermore, VLY antiserum functions as an inhibitor of
VLY–CD59 interaction, mitigating cell lysis. These strategies may have a potential role in the diagnosis and treatment of BV.
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Introduction
Bacterial vaginosis (BV) is the most common vaginal infection
worldwide and is associated with significant adverse consequences
including and preterm labor and delivery [1,2], post-partum
endometritis [3], and an increased risk of HIV acquisition [4,5,6].
Reported prevalence rates range from 10–40% depending upon
the population studied [7]. However, suboptimal methods of
diagnosis and a high percentage of asymptomatic patients make
the true prevalence of BV difficult to ascertain.
The pathogenesis of BV remains poorly understood. It is most
commonly defined as a pathological state characterized by the loss
of normal vaginal flora, particularly Lactobacillus species, and
overgrowth of other microbes including Gardnerella vaginalis,
Bacteroides species, Mobiluncus species, and Mycoplasma hominis.
Recent data however, suggest a primary role for G. vaginalis as a
specific and sexually transmitted etiological agent in BV, as was
initially postulated by Gardner and Dukes in 1955 [8,9,10].
Our laboratory has recently sequenced and characterized the
human-specific, pore-forming toxin produced by G. vaginalis
known as vaginolysin (VLY) [11]. VLY is a member of the
cholesterol-dependent cytolysin (CDC) family of toxins and
recognizes the complement regulatory molecule CD59 on the
surface of human cells. The VLY-CD59 interaction is believed to
play a critical role in the pathogenesis of BV and the development
of its associated complications.
We hypothesize that novel antibody-based techniques may be
useful for detection and quantification of VLY production. These
strategies may represent a substantial improvement in existing
methods of BV diagnosis. Furthermore, antibodies generated
against VLY may disrupt VLY-CD59 binding, thereby reducing
its toxic effects on human cells.
Materials and Methods
Ethics statement
The use of human erythrocytes from healthy adult volunteers
following verbal informed consent was approved by the Columbia
University Institutional Review Board (Protocol IRB-AAAC5641).
Bacterial strains and cell lines
G. vaginalis strains 14018, 14019 and 49145 were purchased
from ATCC. ARG3 is a clinical isolate of G. vaginalis kindly
provided by Susan Whittier. All G. vaginalis strains were grown in
brain heart infusion supplemented with 10% fetal bovine serum
(HyClone), 5% Fildes enrichment (Remel) and 4 ng/ml of
amphotericin. Cultures were incubated at 37uC and 5% CO2.
Human cell lines were purchased from ATCC. Human cervical
endothelial cells (HeLa, ATCC CCL-2) were grown at 37uC and
5% CO2 in minimal essential medium (Invitrogen) supplemented
with 10% fetal bovine serum and 10 mg/ml ciprofloxacin. Human
vaginal endothelial cells (VK2, ATCC CRL-2616) were grown in
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EGF, 0.05 mg/ml bovine pituitary extract and 0.4 mM calcium
chloride [12].
Cloning, expression, and purification of VLY
The genomic region encoding VLY was amplified from G.
vaginalis 14018 as described [11]. Improved purity and greater
yield were achieved by generating a truncated construct (excluding
the first 50 amino acids from the N-terminal region) using the
primer VLY50up (59- GCCGCCCATATGTCGTTGAATAAT-
TATTTGTGG-39) along with the previously described V6 primer
[11]. The PCR product was cloned into the pET28a vector
(Novagen), confirmed by sequencing, and transformed into E. coli
BL21-AI competent cells (Invitrogen) for expression and purifica-
tion as described [11]. The lytic activity of this truncated
recombinant toxoid was unaltered (data not shown).
Generation of antibodies
Purified VLY toxin was generated and submitted to Cocalico
Biologicals (Reamstown, PA). According to their protocol, adult
rabbits were injected with a minimum of 100 mg antigen mixed
with Complete Freund’s Adjuvant subcutaneous and/or intra-
muscularly at multiple sites. Booster doses containing a minimum
of 50 mg antigen mixed with Incomplete Freund’s Adjuvant were
administered on days 14, 21 and 49. A test bleed was performed
on day 56. Prior to the first immunization, serum was collected
from each rabbit to serve as negative control.
Immunofluorescence
G. vaginalis 14018 was grown to in culture media and bacterial
cells were fixed on a glass chamber slide using 4% paraformal-
dehyde. Non-specific binding sites were blocked using 5% normal
donkey serum and 0.2% triton X-100. Pre-immune or immune
serum was added to each slide (1:500 dilution) for 1 h at room
temperature. Following serial washes with PBS and 0.2% triton X-
100, donkey anti-rabbit conjugated to Alexa Fluor (AF)-488
(Invitrogen; 1:1000 dilution) was added for 30 min in the dark
with gentle shaking. After washing, chambers were removed from
the slide and cover slips were mounted with ProLong Gold
antifade with DAPI (Invitrogen). Slides to which no primary
antibody was added served as negative controls.
Western blotting
G. vaginalis 14018 was grown on an HBT plate and fresh
colonies were resuspended in lysis buffer (BugBuster, EMD
Chemicals, Gibbstown, NJ) with benzonase nuclease. The lysate
was boiled and separated on a 10% polyacrylamide gel. Proteins
were transferred to polyvinylidene difluoride membranes, blocked
with 5% milk and probed using rabbit polyclonal anti-VLY
antiserum (1:500,000 dilution). Detection was with HRP-conju-
gated anti-rabbit IgG (Santa Cruz Biotechnology) and ECL.
Membranes probed with pre-immune serum served as a negative
control.
ELISA based assay for VLY production
Four strains of G. vaginalis (14018, 14019, 49145, and ARG3)
were grown on HBT plates, and colonies were scraped and
inoculated into 30 ml of liquid media. A 500 ml aliquot of each
culture was obtained every 6 hours for determination of OD600.
An additional 1 ml sample from each was pelleted by centrifuga-
tion and supernatant stored at 220uC prior to ELISA.
Immuno-96 MicroWell plates (Nunc) were coated with anti-
pneumolysin antibody (clone 1F11, previously shown to cross-
react with VLY) diluted 1:500 in coating buffer (0.1 M sodium
carbonate, pH: 9.5) and incubated at 4uC overnight. Wells were
washed with PBS and 0.05% Tween 20. Non-specific binding sites
were blocked using PBS with 10% fetal bovine serum for 1 h.
Supernatants (100 ml) were added to each well and plates were
incubated at room temperature for 2 h. Known concentrations of
recombinant VLY toxin diluted in G. vaginalis culture media were
used as standards. Rabbit polyclonal anti-VLY antiserum (diluted
1:1000 in blocking solution) was added to each well for 30 min at
room temperature. After washing, goat anti-rabbit HRP antibody
(Santa Cruz Biotechnology, 1:1000 dilution) was added for
30 min. Wells were thoroughly washed and 100 ml of TMB
substrate (Thermo Scientific) was added to each well and plate was
incubated in the dark for 15 min. 50 ml of stop solution (2N
sulfuric acid) was added to each well and OD450 determined.
Hemolysis assay
Human blood was obtained by venipuncture, and erythrocytes
were immediately isolated by centrifugation and repeated washing
in sterile HBSS. A 1% solution of packed erythrocytes in sterile
PBS was prepared and added to a 96-well polystyrene V-bottomed
plate (100 ml/well). Hemolysis assay was performed as described
[11]. Where indicated, toxin was preincubated with pre-immune
or immune sera for 30 min at 4uC prior to use in the assay.
Cytotoxicity assay
24-well plates were seeded with VK2 or HeLa human epithelial
cells in appropriate media and grown to .90% confluence.
12 hours prior to use, HeLa cells were weaned from serum.
Recombinant VLY toxin diluted in media (10 mg/ml) or vehicle
control was added to each well. Where indicated, toxin was
preincubated with pre-immune or immune sera for 30 min at 4uC
prior to use in the assay. The plates were incubated for 45 min at
37uC and 5% CO2. Supernatant was removed and the concentra-
tion of lactate dehydrogenase was determined using a commercial
kit (Roche) according to the manufacturer’s instructions.
Statistical analysis
Data were expressed as mean6SEM and compared using one-
way analysis of variance (ANOVA) with Tukey post-test for
comparison of individual groups. (Prism, GraphPad Software)
Results
VLY antiserum detects G. vaginalis by western blot and
immunofluorescence
Using polyclonal immune serum, we developed novel antibody-
based techniques for VLY detection. Western blot analysis of lysed
G. vaginalis 14018 revealed a single band using polyclonal immune
serum as the primary antibody (Figure 1A). This corresponds to
the predicted 57 kDa molecular mass of VLY and to our prior
findings using cross-reacting anti-pneumolysin antibody [11].
There were no visible bands detected on membranes probed with
pre-immune serum and processed identically (data not shown).
Immunofluorescent detection of VLY associated with whole G.
vaginalis was detected microscopically using immune serum and
fluorescently labeled anti-rabbit secondary antibodies (Figure 1B).
Preimmune serum did not lead to detectable fluorescence of G.
vaginalis (Figure 1B).
ELISA detects VLY production by G. vaginalis
Utilizing polyclonal immune serum, we developed a sandwich
ELISA capable of quantifying VLY production in vivo. We used a
Vaginolysin Antibody Methods
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capture and polyclonal anti-VLY for detection. Four strains of
G. vaginalis (including three well characterized laboratory strains
and one clinical isolate) were inoculated into liquid media and
bacterial growth curves were generated as determined by optical
density (600 nm). All strains of G. vaginalis grew at similar rates in
liquid media (Figure 2B). We assessed in vivo toxin production at
regular intervals (every 6 h) during growth. The sensitivity of the
assay was at the level of ng/ml concentrations in bacterial
supernatants. VLY production peaked at 24–36 hr in all four
strains and correlated with bacterial concentration (Figure 2A).
Antiserum against VLY inhibits toxin-mediated cytolysis
Human erythrocytes are susceptible to VLY-mediated hemolysis
at low ng/ml concentrations (Figure 3A). We hypothesized that
antiserum would neutralize VLY, mitigating its cytolytic activity. In
ordertotestthishypothesis,VLYwaspre-incubatedwith polyclonal
immune serum (1:50 dilution) for 30 minutes prior to exposure to
human erythrocytes. Pre-incubation with immune serum resulted in
significantly less hemolysis compared to cells exposed to untreated
or pre-immune serum-treated VLY (Figure 3A). Inhibition of
VLY-mediated lysis by immune serum was dose-dependent
(Figure 3B) and was significant even at the highest (1:500) dilution.
Figure 1. Antibody techniques for the detection of VLY. (A) Western blot of G.vaginalis 14018 lysate probed with rabbit polyclonal antiserum
(1:500,000 dilution). Numbers represent approximate MW in kD (B) Immunofluorescent detection of VLY production by G.vaginalis using pre-immune
rabbit serum (bottom panel) or anti-VLY antiserum (top panel). Anti-rabbit IgG-AF488 was the secondary antibody (green). DNA staining with DAPI
demonstrates bacteria in both panels (blue). Scale bar: 10 mm.
doi:10.1371/journal.pone.0005207.g001
Figure 2. Quantification of VLY production in vivo. (A) Detection of VLY in supernatants from four different strains of G. vaginalis supernatants
by ELISA at various time points following inoculation of broth culture. (B) Bacterial growth (OD600) over the course of the experiment.
doi:10.1371/journal.pone.0005207.g002
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believed to be critical for the development of bacterial vaginosis
and its associated morbidities. Inhibition of VLY-mediated cell
lysis in these tissues may therefore, have important physiologic
relevance. Using an LDH assay, we assessed the cytolytic activity
of VLY in human cervical epithelial cell (HeLa) and vaginal
epithelial cells (VK2). VLY-mediated lysis of both HeLa cells
(Figure 4A) and VK2 cells (Figure 4B) was markedly reduced in
the setting of immune serum.
Discussion
Existing methods of diagnosis for BV are suboptimal and
frequently underutilized by practitioners. A recent study by Hogan
et al. reports that the prevalence of BV among pregnant women
varies greatly depending on the diagnostic criteria used [13].
Furthermore, the authors conclude that the methodology employed
by most physicians would understate the true prevalence of BV.
Established in 1983, Amsel’s criteria are widely accepted as the
best available means for diagnosing BV in the clinical setting and
require at least three of the following conditions be present:
vaginal discharge, amine odor, pH.4.5 and the presence of clue
cells [14]. These criteria are complex, somewhat subjective, and
necessitate that microscopy equipment be present on site.
Moreover, because the vast majority of women with BV are
asymptomatic, application of these criteria may be impractical. A
study by Keane et al. noted that the Amsel criteria were used by
only 65% of clinics in the UK and only 31% of the practitioners
utilized all four criteria in their assessment [15].
The Nugent scoring system for interpretation of Gram-stained
vaginal smears was put forth in an attempt to standardize
diagnosis of BV and increase inter-rater reliability [16]. Scores are
assigned to Gram-stained vaginal smears according to the number
of specific bacterial morphotypes seen per microscopic 10006
visual field. While the Nugent scoring system exhibits superior
sensitivity and specificity compared to the Amsel criteria [17], its
use remains largely restricted to research protocols. Furthermore,
questions regarding the risk of potential morbidities and the need
for antimicrobial therapy in those women found to have
‘‘intermediate flora’’ remain unanswered [18,19].
The sheer prevalence of BV and its associated morbidities justify
the exploration and development of improved diagnostic strategies
easily incorporated into diverse clinical settings. Several alternative
diagnostic methodologies focusing upon the detection of microbial
Figure 3. Polyclonal immune serum inhibits VLY-mediated hemolysis. (A) Human erythrocytes were exposed to varying concentrations of
purified recombinant VLY for 30 min. Cells were pelleted, and hemoglobin release was determined by OD415 of the supernatant. Values were
normalized to 100% lysis. When indicated, VLY was preincubated with pre-bleed (VLY+PB) or immune serum (VLY+IS) diluted 1:50 for 30 min prior to
use in the assay. (B) Erythrocytes were exposed to VLY (500 ng/ml), VLY+PB, or serial dilutions of VLY+IS (P,0.01 for VLY+PB versus all VLY+IS
dilutions).
doi:10.1371/journal.pone.0005207.g003
Figure 4. Immune serum inhibits VLY-mediated lysis of human cervical and vaginal cells. Human cervical (A, HeLa) or vaginal (B, VK2)
epithelial cells were exposed to VLY (10 mg/ml), VLY+PB, or VLY+IS. Lysis was measured by LDH release assay following 30 min of incubation with
toxin. Values were normalized to 100% lysis for each cell line (P,0.05 for VLY+IS versus VLY+PB for HeLa and VK2 cell lines).
doi:10.1371/journal.pone.0005207.g004
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have been proposed in recent years. These include detection of
bacterial sialidases, determination of amine levels, and measure-
ment of proline aminopeptidase activity [20,21,22]. While these
techniques are relatively simple, rapid and inexpensive, they fail to
identify the specific microbial pathogens present.
A potential role for novel, molecular based techniques for the
diagnosis of BV has recently emerged. Importantly, preliminary
studies evaluating these PCR-based strategies have provided
additional evidence for G. vaginalis as the primary etiologic agent
of BV [23,24,25]. Menard et al. analyzed 213 vaginal samples
from pregnant women using a molecular probes targeting 8 BV–
related organisms [24]. These authors report that an increased
load of G. vaginalis (.10
9 copies of G. vaginalis DNA per ml) had
both high negative and positive predictive values for the diagnosis
of BV. While these molecular based diagnostic strategies are
promising, the required expertise, laboratory resources and
expense limits their use in the primary care setting.
We demonstrate here that antibody-based techniques are an
effective means of identifying G. vaginalis through the detection of
its pore-forming toxin VLY. The ELISA based assay in particular,
is sensitive, robust and directly correlates with the concentration of
G. vaginalis, reported to be an independent predictor of BV and
subsequent preterm delivery [23,24,25,26]. In addition to the
diagnostic utility of these antibody-based strategies, they may have
an additional role in the treatment of BV. We demonstrated
antibody-mediated inhibition of lysis of erythrocytes as well as the
likely target cell of VLY in vivo, female genital tract epithelial cells.
While successful eradication of BV in pregnant women is possible
utilizing appropriate antimicrobial therapy, many women exhibit
persistent symptoms, recurrent disease, and persistence of
abnormal vaginal flora. Furthermore, several large clinical trials
have demonstrated that the use of antibiotics in these women has
not been associated with a reduction in preterm birth [27,28]. The
failure of antimicrobial therapy to reduce BV-associated preterm
labor may be attributable its inability to mitigate the resultant
inflammatory cascade already underway.
The human-restricted activity of VLY represents a barrier to
the study of pathogenesis and candidate therapeutic strategies.
Disruption of the interaction of VLY with its host cell receptor,
human CD59, may represent a novel approach to the treatment of
BV. We demonstrated that polyclonal immune serum functions to
inhibit the VLY-CD59 interaction, thereby reducing its toxic
effects on a variety of human cell lines. These finding may serve as
a preliminary basis for in vivo studies investigating a potential role
for immunotherapy in the management of women with BV and
the development of vaccine based strategies for disease prevention.
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